The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.
about
Amyloid beta precursor protein and prion protein have a conserved interaction affecting cell adhesion and CNS developmentα-Synuclein occurs physiologically as a helically folded tetramer that resists aggregationGSPE interferes with tau aggregation in vivo: implication for treating tauopathyForever young: mechanisms of natural anoxia tolerance and potential links to longevityLinking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD)Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathwaysAutophagy and Neurodegeneration: Insights from a Cultured Cell Model of ALSTargeting heat shock proteins to modulate α-synuclein toxicityMultitasking in the mitochondrion by the ATP-dependent Lon proteaseMitochondrial dysfunction and oxidative stress in Parkinson's diseaseCheckpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous SystemMolecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblastsFormation of amyloid fibrils from β-amylaseEvaluating the fitness cost of protein expression in Saccharomyces cerevisiae.Investigating Structure and Dynamics of Proteins in Amorphous Phases Using Neutron Scattering.A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluationTDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.A novel Markov Blanket-based repeated-fishing strategy for capturing phenotype-related biomarkers in big omics dataDopamine-induced conformational changes in alpha-synucleinTau mutants bind tubulin heterodimers with enhanced affinity.The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease.Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene.Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS).FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.Amyloid-beta immunotherapy for Alzheimer's diseasePotential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein.Visualization of endoplasmic reticulum subdomains in cultured cells.Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.Bim links ER stress and apoptosis in cells expressing mutant SOD1 associated with amyotrophic lateral sclerosis.Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein.Protein aggregation caused by aminoglycoside action is prevented by a hydrogen peroxide scavenger.Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease.The role of apolipoprotein E in Alzheimer's disease.Antisense therapy in neurologyChanges in the expression of four heat shock proteins during the aging process in Brachionus calyciflorus (rotifera).The NADPH metabolic network regulates human αB-crystallin cardiomyopathy and reductive stress in Drosophila melanogasterOverexpression of Q-rich prion-like proteins suppresses polyQ cytotoxicity and alters the polyQ interactome.From interaction to co-association --a Fisher r-to-z transformation-based simple statistic for real world genome-wide association study
P2860
Q24305972-1C25C5E0-BF52-4856-9ABB-E37C17C565B2Q24605589-9E0137E6-0AC8-47D3-8476-DD8BF2CA3E77Q24628862-4DCFE35F-0313-4B55-BD94-C048C7124748Q24633593-24B66499-43AC-4C23-9698-37F3C4AC7CC3Q26752685-6D01023F-70C2-4CA9-A796-8276F37A618FQ26779424-ADEFA567-93AC-4644-841A-663C519F4250Q26796599-19095322-2989-4B15-A15A-762B663DFF63Q26827066-09B2F143-C990-416A-B06F-65A075A32CDBQ27003208-1EFCD7EA-978B-49CD-A3FC-4B2A2395FE52Q27014051-470D1FF8-5F86-4FEB-8394-3C907FCB1F0CQ28066906-81D22766-0BCC-4019-94CB-366266A73E8FQ28474877-E993E0BD-8BC8-4867-B027-5AE71630A898Q28586287-DEC9CB7E-5B03-46CA-BA01-A32C31DFC14AQ30354567-C10C9FA3-FBAF-4A46-892A-B523A9269BD3Q30398032-06F02274-24BE-4331-A979-60B663F3D4A1Q30487256-4CA106F2-7790-4771-8E31-287FE884437FQ30490978-A43591A3-5934-43B1-B349-BAA7F2ED28FEQ31055003-73E1115E-F4CE-472F-AC2C-27ACC8D39B07Q33500157-3AAFAA7F-9DEF-4AAD-BEF9-041D823863ACQ33674452-999C612E-6EDA-48FE-82A9-4E84D9A31D17Q33748087-075E59A9-24B0-4003-81BC-19CCC0736CA3Q33757721-0272A897-72E0-4358-BBD1-18725A3CB66CQ33778710-64C451B2-EBDB-4C9A-AD8C-800F854CECAEQ33782133-F4737F7A-67BE-4214-9D41-88CC1DC76A5FQ33799562-20D882DB-6F4C-4F71-811F-02690C5202A4Q33908722-89392133-164A-4163-BD9F-5C86D01EC3D7Q33954737-C43483A7-3B7F-4FE8-8386-7D23690A61E6Q34002451-D6EF17A9-A86B-4015-979F-600593640AA8Q34014996-CC1E0A5E-5B48-4259-8D12-5D0FBC49ACD1Q34028511-DDC4969D-7960-4A62-BCE2-EB307CCCDD6BQ34241864-02F4B22D-2065-4CB8-8BCC-B7BFBECA26F4Q34380871-475D0482-4ABB-455F-85CB-91804B3777B2Q34466043-FCFDD257-ACC8-426B-837A-A730043DF436Q34482196-8C2C0137-91AD-4AA0-99A7-81211B91EBC7Q34603092-2BE5F45C-2C1D-488B-8790-BC2CE2D8F2DEQ34608717-7B7D1739-BF9E-4C2E-B2D7-64C12CD772D9Q34688418-A4216F2D-D66B-45E2-8ADB-F5DBA27C8032Q34789370-C2D04E74-090E-4081-AF89-0544155F3BE5Q34793446-63563C5B-4EBA-4BBE-8EAE-0F6E267C9DD0Q34907294-257F467D-598A-48D7-A006-46F0AB1A611A
P2860
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The two faces of protein misfo ...... in neurodegenerative diseases.
@en
The two faces of protein misfo ...... in neurodegenerative diseases.
@nl
type
label
The two faces of protein misfo ...... in neurodegenerative diseases.
@en
The two faces of protein misfo ...... in neurodegenerative diseases.
@nl
prefLabel
The two faces of protein misfo ...... in neurodegenerative diseases.
@en
The two faces of protein misfo ...... in neurodegenerative diseases.
@nl
P2860
P50
P356
P1433
P1476
The two faces of protein misfo ...... in neurodegenerative diseases.
@en
P2860
P304
P356
10.1038/SJ.EMBOJ.7601930
P407
P577
2008-01-01T00:00:00Z